Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 4/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | XDH | P47989 | 2/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.52 |
| ▸ | GFER | P55789 | 1/20 | 0.52 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.52 |
| ▸ | RELA | Q04206 | 1/20 | 0.52 |
| ▸ | FUT7 | Q11130 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | CA12 | O43570 | 4/20 | 0.52 |
| ▸ | CA1 | P00915 | 4/20 | 0.52 |
| ▸ | CA2 | P00918 | 4/20 | 0.52 |
| ▸ | CA7 | P43166 | 4/20 | 0.52 |
| ▸ | CA9 | Q16790 | 4/20 | 0.52 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.52 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.52 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1516592 | 0.85 | GAA (0.44) | GAALMNAKDM4EXDHPOLB | |
| SCHEMBL17627594 | 0.85 | AKR1C4 (0.60) | GAALMNAKDM4EXDHPOLB | |
| SCHEMBL27201757 | 0.85 | CA12 (0.47) | GAALMNAKDM4EXDHPOLB | |
| SCHEMBL23714914 | 0.83 | CA12 (0.46) | GAALMNAKDM4EXDHPOLB | |
| SCHEMBL24379448 | 0.83 | CYP3A4 (0.49) | GAALMNAKDM4EXDHPOLB | |
| SCHEMBL3310733 | 0.83 | KDR (0.43) | GAALMNAKDM4EXDHPOLB | |
| SCHEMBL3489830 | 0.81 | GAA (0.42) | GAALMNAKDM4EXDHPOLB | |
| SCHEMBL16088526 | 0.81 | CA12 (0.44) | GAALMNAKDM4EXDHPOLB | |
| SCHEMBL1620851 | 0.81 | FAAH (0.55) | GAALMNAKDM4EPOLBGFER | |
| SCHEMBL30881900 | 0.81 | CA12 (0.44) | GAALMNAKDM4EXDHPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025108255-A1 | POLYCYCLIC DERIVATIVE, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海齐鲁制药研究中心有限公司 | 2025-05-30 | — | — | WO | disclosed |
| WO-2025063272-A1 | NICOTINAMIDE DERIVATIVE AND AGRICULTURAL AND HORTICULTURAL PLANT DISEASE CONTROL AGENT | クミアイ化学工業株式会社 | 2025-03-27 | — | — | WO | disclosed |
| US-12065433-B2 | Positive allosteric modulators of the muscarinic acetylcholine receptor M1 | VANDERBILT UNIVERSITY (US) | 2024-08-20 | — | — | US | disclosed |
| WO-2024050433-A1 | ALLOSTERIC MODULATORS OF ANDROGEN RECEPTOR COACTIVATOR RECRUITMENT FOR CRPC THERAPY | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2024-03-07 | — | — | WO | disclosed |
| US-20230219986-A1 | NOVEL AMINOPYRIMIDINE EGFR INHIBITOR | QILU PHARMACEUTICAL CO., LTD. (CN) | 2023-07-13 | — | — | US | disclosed |
| US-20230219986-A1 | NOVEL AMINOPYRIMIDINE EGFR INHIBITOR | QILU PHARMACEUTICAL CO., LTD. (CN) | 2023-07-13 | — | — | US | disclosed |
| EP-4129996-A1 | NOVEL AMINOPYRIMIDINE EGFR INHIBITOR | QILU PHARMACEUTICAL CO., LTD. (CN) | 2023-02-08 | — | — | EP | disclosed |
| US-20210355114-A1 | POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M1 | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-11-18 | — | — | US | disclosed |
| US-10752604-B2 | C-glucoside derivative containing fused phenyl ring or pharmaceutically acceptable salt thereof, process for preparing same, and pharmaceutical composition comprising same | Je II Pharmaceutical Co., Ltd. (KR) | 2020-08-25 | — | — | US | disclosed |
| EP-3404033-B1 | C-GLUCOSIDE DERIVATIVE CONTAINING FUSED PHENYL RING OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PROCESS FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | JEIL PHARMACEUTICAL CO LTD (KR) | 2020-08-05 | — | — | EP | disclosed |
| EP-1641784-A1 | 4-(AMINOMETHYL)-PIPERIDINE BENZAMIDES AS 5HT4 -ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-04-05 | — | — | EP | disclosed |
| EP-1638961-A1 | HETEROCYCLIC SUBSTITUTED 4-(AMINOMETHYL)-PIPERIDINE BENZAMIDES AS 5HT4-ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-03-29 | — | — | EP | disclosed |
| EP-1560630-A2 | 7H-DIBENZO[B,G][1,5]DIOXOCIN-5-ONE DERIVATIVES AND USE THEREOF | Bayer HealthCare AG (DE) | 2005-08-10 | — | — | EP | disclosed |
| WO-2005058228-A2 | COMT INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-06-30 | — | — | WO | disclosed |
| WO-2005058228-A2 | COMT INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-06-30 | — | — | WO | disclosed |
| US-20050137162-A1 | New COMT inhibitors for the treatment of depression and impaired cognition | F. HOFFMANN-LA ROCHE AG (CH) | 2005-06-23 | — | — | US | disclosed |
| WO-2005003124-A1 | HETEROCYCLIC SUBSTITUTED 4-(AMINOMETHYL)-PIPERIDINE BENZAMIDES AS 5HT4-ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-01-13 | — | — | WO | disclosed |
| WO-2005000837-A1 | AMINOSULFONYL SUBSTITUTED 4-(AMINOMETHYL)-PIPERIDINE BENZAMIDES AS 5HT4-ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-01-06 | — | — | WO | disclosed |
| WO-2005000838-A1 | 4-(AMINOMETHYL)-PIPERIDINE BENZAMIDES AS 5HT4-ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-01-06 | — | — | WO | disclosed |
| WO-2004039453-A2 | 7H-DIBENZO[B,G][1,5]DIOXOCIN-5-ONE DERIVATIVES AND USE THEREOF | BAYER HEALTHCARE AG (DE) | 2004-05-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12065433-B2 | Positive allosteric modulators of the muscarinic acetylcholine receptor M1 | CHRM1, CHRM2, CHRM4 | GAA 3074/4885LMNA 3939/4885KDM4E 1530/4885 |
| US-20210355114-A1 | POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M1 | CHRM1, CHRM2, CHRM4 | GAA 3074/4885LMNA 3939/4885KDM4E 1530/4885 |
| US-20230219986-A1 | NOVEL AMINOPYRIMIDINE EGFR INHIBITOR | EGFR, ERBB2, ERBB4 | GAA 3093/4885LMNA 4573/4885KDM4E 1344/4885 |
| US-10752604-B2 | C-glucoside derivative containing fused phenyl ring or pharmaceutically acceptable salt thereof, process for preparing same, and pharmaceutical composition comprising same | SLC5A2, SLC5A1, UGGT1 | GAA 163/4885LMNA 4481/4885KDM4E 1061/4885 |
| US-20050137162-A1 | New COMT inhibitors for the treatment of depression and impaired cognition | COMT, MAOB, TPH1 | GAA 110/4885LMNA 4305/4885KDM4E 1075/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.